Having trouble accessing articles? Reset your cache.

As itacitinib stumbles in acute GvHD, Incyte turns to chronic setting

Incyte’s discontinuation of itacitinib’s development in acute graft-versus-host disease after a Phase III miss has muddied the outlook for the JAK-1 inhibitor in the larger setting of chronic GvHD and marks a setback as the company aims to diversify beyond Jakafi.

Incyte

Read the full 416 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE